Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for chronic liver and intestinal diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. It moved from Phase III stage of development to pre-registration for primary biliary cholangitis (PBC) worldwide excluding certain Asian countries licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon). The product is also under development for the treatment of nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US. This comprehensive SWOT profile of Intercept Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations.